**Summary**
ECO Animal Health Group PLC, a global animal health company, has announced its detailed commercialization strategy for ECOVAXXIN® MS, a poultry vaccine against Mycoplasma synoviae, following the European Commissions marketing authorization in December 2025. The vaccine aims to immunize layer and breeder chickens, reducing economic losses caused by infections, including air-sac and foot-pad lesions and decreased egg production.
The company plans a phased launch across key European territories in 2026 and 2027, leveraging its existing commercial network and strategic distribution partnerships covering over 220 million layer birds annually in the EUs top seven poultry markets. A pre-launch phase includes distributor training, technical assessments, and marketing activities, culminating in an official launch event in Madrid, Spain, from June 30 to July 1, 2026, followed by regional events.
ECOVAXXIN® MS is expected to be immediately margin accretive, with a material contribution to EBITDA anticipated in the 2027/2028 financial year. The launch positions ECO as a comprehensive Mycoplasma solutions provider, complementing its lead product Aivlosin®. The company’s CEO, David Hallas, and Chief Commercial Officer, Andrew Buglass, emphasized the strategic importance of this launch, highlighting the vaccine’s differentiated value and the readiness of the commercial network for successful market entry.